← All trials
NCT04553016
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 19, 2020
- Primary completion
- Dec 31, 2021
- Completion date
- Dec 31, 2021
- First posted
- Sep 17, 2020
- Last posted
- Sep 21, 2020
- Enrollment
- 88
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OxfordLead sponsor
- University of OxfordOverall official - principal investigator
- University of NairobiOverall official - principal investigator
- University of NairobiCollaborator
- Wellcome TrustCollaborator
- International AIDS Vaccine InitiativeCollaborator
- Imperial College LondonCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- Center for Family Health Research in ZambiaOverall official - principal investigator
- Center for Family Health Research in ZambiaCollaborator
- Wellcome TrustOverall official - principal investigator
- Medical Research CouncilOverall official - principal investigator
- Medical Research CouncilCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.